Vir Biotechnology To Present Late-Breaking Data From Its Ongoing Phase 2 Chronic Hepatitis B And Delta Trials At AASLD's The Liver Meeting 2023
Portfolio Pulse from Benzinga Newsdesk
Vir Biotechnology (NASDAQ:VIR) will present new data from its Phase 2 trials evaluating VIR-3434 and VIR-2218 for chronic hepatitis B and delta at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting in November 2023. The company will host an investor conference call to discuss the data on November 13th. VIR-3434 and VIR-2218 are investigational treatments designed to block entry of hepatitis B and delta viruses into hepatocytes and reduce the level of virions and subviral particles in the blood.
November 10, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Vir Biotechnology's upcoming presentation of new data from its Phase 2 trials could potentially impact its stock price. Positive results could increase investor confidence, while negative results could have the opposite effect.
The upcoming presentation of new data from Vir Biotechnology's Phase 2 trials is highly relevant to the company and its stock price. The results of these trials could potentially influence investor sentiment and thus the stock price. However, without knowing the results of the trials, it is difficult to predict the direction of the impact.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100